On September 20th, 2024, the U.S. Food and Drug Administration (FDA) approved MedImmune and AstraZeneca's FluMist® (influenza virus vaccine) for self-administration. FluMist® is administered intranasally and is approved for the prevention of influenza caused by influenza virus subtypes A and B in individuals 2 through 49 years of age. The manufacturer plans to make FluMist available through an online pharmacy for Fall of 2025 that will write the prescription and ship the vaccine directly to patients.
https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-spray-influenza-vaccine-self-or-caregiver-administration?utm_content=310294359&utm_medium=social&utm_source=facebook&hss_channel=fbp-886153778131997
